Perphenazine

Depression, Generalized Anxiety Disorder, Schizophrenia + 8 more
Treatment
12 FDA approvals
20 Active Studies for Perphenazine

What is Perphenazine

PerphenazineThe Generic name of this drug
Treatment SummaryAn antipsychotic medication with effects similar to that of chlorpromazine, a medicine used to treat psychosis.
Perphenazineis the brand name
Perphenazine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Perphenazine
Perphenazine
1987
153

Approved as Treatment by the FDA

Perphenazine, also known as Perphenazine, is approved by the FDA for 12 uses like Depression and moderate Anxiety .
Depression
Used to treat Depression in combination with Amitriptyline
moderate Anxiety
Used to treat moderate Anxiety in combination with Amitriptyline
Schizophrenia
Helps manage Schizophrenia
severe Nausea and vomiting
Anxiety
Used to treat severe Anxiety in combination with Amitriptyline
Generalized Anxiety Disorder
Used to treat Anxiety in combination with Amitriptyline
Mental Depression
Used to treat severe Depressed mood in combination with Amitriptyline
Chronic Physical Illness
Used to treat Chronic Physical Illness in combination with Amitriptyline
Mental Depression
Used to treat moderate Depressed mood in combination with Amitriptyline
Nausea
severe agitation
Used to treat severe agitation in combination with Amitriptyline
moderate Agitation
Used to treat moderate Agitation in combination with Amitriptyline

Effectiveness

How Perphenazine Affects PatientsPerphenazine is a member of the phenothiazine class of drugs, which work on the central nervous system and block the action of dopamine in the brain. It is much more powerful than other similar drugs, and is used as a highly effective antipsychotic. In terms of side effects, Perphenazine is about as likely and severe to cause early and late extrapyramidal side effects as Haloperidol.
How Perphenazine works in the bodyPerphenazine blocks the activity of dopamine D1 and D2 receptors. This helps control nausea and vomiting by preventing the dopamine neurotransmitter from stimulating the receptors in the areas of the brain responsible for these symptoms. Perphenazine also binds to alpha andrenergic receptors, which are responsible for activating a cell signaling pathway.

When to interrupt dosage

The proposed measure of Perphenazine is contingent upon the determined condition, like Generalized Anxiety Disorder, moderate Agitation and Depression. The degree of dosage varies as per the approach of delivery (e.g. Syrup - Oral or Tablet, sugar coated - Oral) featured in the table below.
Condition
Dosage
Administration
Depression
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Nausea
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Anxiety
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Chronic Physical Illness
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
moderate Anxiety
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
moderate Agitation
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Mental Depression
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Mental Depression
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Generalized Anxiety Disorder
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
Schizophrenia
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral
severe agitation
, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Warnings

Perphenazine has seven contraindications, consequently it should not be taken when any of the conditions specified in the following table occur.Perphenazine Contraindications
Condition
Risk Level
Notes
large dose of CNS depressants
Do Not Combine
Brain Injuries
Do Not Combine
Liver Damage
Do Not Combine
Coma
Do Not Combine
Disease
Do Not Combine
greatly obtunded patients
Do Not Combine
Bone Marrow
Do Not Combine
There are 20 known major drug interactions with Perphenazine.
Common Perphenazine Drug Interactions
Drug Name
Risk Level
Description
Amisulpride
Major
Perphenazine may increase the antipsychotic activities of Amisulpride.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Perphenazine.
Azelastine
Major
Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Dacomitinib
Major
The metabolism of Dacomitinib can be decreased when combined with Perphenazine.
Deutetrabenazine
Major
The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.
Perphenazine Toxicity & Overdose RiskSigns of overdosing on amitriptyline include stupor or unconsciousness, and in some cases, seizures in children. Patients may not regain consciousness for up to two days. The lowest toxic dose for rats is 318mg/kg, and 64mg/kg for mice.
image of a doctor in a lab doing drug, clinical research

Perphenazine Novel Uses: Which Conditions Have a Clinical Trial Featuring Perphenazine?

985 active investigations are currently assessing the potential of Perphenazine to palliate moderate Agitation, Anxiety and Nausea.
Condition
Clinical Trials
Trial Phases
Generalized Anxiety Disorder
181 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
moderate Anxiety
0 Actively Recruiting
Nausea
0 Actively Recruiting
Anxiety
0 Actively Recruiting
moderate Agitation
0 Actively Recruiting
Chronic Physical Illness
1 Actively Recruiting
Not Applicable
severe agitation
0 Actively Recruiting
Depression
304 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Mental Depression
0 Actively Recruiting
Mental Depression
0 Actively Recruiting

Perphenazine Reviews: What are patients saying about Perphenazine?

5Patient Review
12/28/2020
Perphenazine for Schizophrenia
I was originally prescribed 2mg of this medication, but I still felt like evil spirits were touching me. My doctor then increased the dosage to 4mg and then 6mg, and I no longer have those sensations. I am a bit tired during the day, but overall I'm much happier now.
5Patient Review
8/26/2015
Perphenazine for Schizophrenia
I've tried a lot of different medications, but this is the best one I've found so far. It helps me manage my symptoms without making me feel sedated or like a zombie. Life is more worth living with this medication.
5Patient Review
4/2/2016
Perphenazine for Schizophrenia
This medication is highly effective for me with very few side effects. I take it at night to avoid feeling sedated or dizzy during the day.
5Patient Review
2/27/2010
Perphenazine for Mental Disorder with Loss of Normal Personality & Reality
5Patient Review
4/16/2011
Perphenazine for Schizophrenia
This pill has been helping me since I started taking it.
4.7Patient Review
12/22/2019
Perphenazine for Schizophrenia
This medication has been a big help to me in managing my shizoaffective disorder. It's effective at quieting the voices I hear and also helped with negative thinking.
4.3Patient Review
12/12/2013
Perphenazine for Mental Disorder with Loss of Normal Personality & Reality
This medication has been a life-saver for me. I had been experiencing insomnia for 4 days and my meds were adjusted from Abilify to perphenazine. After 2 weeks all of my symptoms were relieved and I can sleep 7-8 hours every night.
4.3Patient Review
10/1/2010
Perphenazine for Mental Disorder with Loss of Normal Personality & Reality
I've tried a lot of different treatments for my bipolar disorder, and this one seems to be working better than anything else I've tried. I'm feeling more stable and less suicidal, which is a huge relief.
4.3Patient Review
3/26/2010
Perphenazine for Schizophrenia
Perphenazine was effective for me, but unfortunately caused permanent impotence.
4.3Patient Review
1/25/2011
Perphenazine for Schizophrenia
This drug has been really helpful for me in terms of organization and slowing down my thoughts. The only downside is that I sometimes feel dizzy when I stand up too quickly, but it's not a huge issue.
4.3Patient Review
1/10/2012
Perphenazine for Mental Disorder with Loss of Normal Personality & Reality
This drug has been effective in silencing the voices I hear as a result of my bipolar II and PTSD. When I first started taking it, I experienced headaches; however, those went away after continued use.
3.3Patient Review
6/7/2010
Perphenazine for Mental Disorder with Loss of Normal Personality & Reality
My doctor prescribed this medication for my insomnia, but I found it actually made it harder to sleep.
3Patient Review
3/10/2011
Perphenazine for Schizophrenia
Many of the symptoms are similar to those of ADHD, such as a lack of organization and follow-through, forgetfulness, and difficulty sleeping regularly.
2.7Patient Review
4/17/2013
Perphenazine for Mental Disorder with Loss of Normal Personality & Reality
ADHD is my diagnosis and the doctor prescribed this to help me focus better in conjunction with Adderall. I haven't seen much of a difference yet.
2.7Patient Review
12/30/2009
Perphenazine for Schizophrenia
2Patient Review
4/26/2010
Perphenazine for Mental Disorder with Loss of Normal Personality & Reality
After being taken off of my other medications and prescribed perphenazine, I've been feeling so much better. It's been six weeks and I can definitely say that this medication has helped to level out my hypomania and depression.

Patient Q&A Section about perphenazine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug perphenazine used for?

"Perphenazine is used to treat symptoms of schizophrenia, such as disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions. Perphenazine is also used to control severe nausea and vomiting in adults."

Answered by AI

Is perphenazine good for anxiety?

"Perphenazine is an effective medication for patients with varying degrees of anxiety and agitation, from mild tension or hyperactivity to severe psychosis or psychomotor hyperactivity."

Answered by AI

Is perphenazine a sedative?

"Perphenazine has properties that help to calm patients and reduce anxiety, making the drug useful for treating psychotic patients who are agitated."

Answered by AI

Is perphenazine used for depression?

"This medicine is used to treat depression that may be accompanied by anxiety or agitation. It is also used to treat schizophrenia."

Answered by AI

Clinical Trials for Perphenazine

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Have you considered Perphenazine clinical trials? We made a collection of clinical trials featuring Perphenazine, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Have you considered Perphenazine clinical trials? We made a collection of clinical trials featuring Perphenazine, we think they might fit your search criteria.Go to Trials
Image of Caron Treatment Centers in Wernersville, United States.

Safe and Sound Protocol for Substance Abuse

18 - 75
All Sexes
Wernersville, PA
This study will explore whether the use of the Safe and Sound Protocol (SSP) app is an effective adjunct to treatment as usual (TAU) in individuals with co-occurring substance use disorders and trauma. This study will recruit 129 participants (100 completers) randomized to receive either active or sham SSP in addition to TAU. Participants will utilize the SSP for a minimum of three hours to a maximum of five hours for a total of seven days. Data will be collected at both pre- and post-test. Data to be collected will include measures on affect, anxiety, personality, mindfulness, and posttraumatic stress disorder symptoms. The SSP has shown effectiveness in reducing symptoms of anxiety, depression, and trauma symptoms in pilot studies conducted at other locations. This will be the first study to examine the effectiveness of SSP with individuals with co-occurring SUD and trauma.
Waitlist Available
Device
Caron Treatment CentersErin Deneke, PhD
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Have you considered Perphenazine clinical trials? We made a collection of clinical trials featuring Perphenazine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security